Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
Evolv expands partnership with Gillette Stadium and becomes official provider for fan security screening
Evolv has renewed and expanded its partnership with Gillette Stadium, which began in 2021, so that KI-supported Evolv Express security lanes will be installed at additional entrances. The systems are designed to detect concealed weapons at normal walking speed and have already screened more than seven million visitors at the stadium. The contract extension strengthens Evolv’s presence in the greater Boston area; the company reports 36.6% revenue growth last year, Q2 revenue of $32.5 million (+29%) and remains unprofitable despite strong demand (negative EBITDA). Analyst reactions raised price targets and ratings but highlighted the still-present valuation premium. » Más en de.investing.com
Evolv Technologies reaches new 52-week high at $7.45
Shares of Evolv Technologies Holdings Inc. rose to a new 52-week high of $7.45 after the stock gained about 143.77% over the past year. The company reported revenue growth of 36.71%, a positive EBITDA in the first quarter, a $75 million credit facility from MidCap Financial and a $19.36 million school contract with Gwinnett Schools; analyst price targets range from $5.50 to $8.25. Positive analyst revisions (Northland, Craig-Hallum, Lake Street) and the resolution of an FTC probe are cited as drivers of the optimistic sentiment. » Más en de.investing.com
Evolv Technologies reaches new 52-week high after strong growth and positive analyst ratings
Evolv Technologies' stock climbed to a 52-week high of $7.10, supported by revenue growth of 36.71% and strong performance over the past year. The company also secured a $75 million credit facility to strengthen its subscription-based business and significantly exceeded revenue expectations in the first quarter. Analysts upgraded the stock to 'Outperform' or 'Buy' due to improved financial metrics and strategic initiatives. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | - |
| Beneficio neto | -688,15 mil | - |
| EBITDA | -839,6 mil | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 17,38 M € |
Número de acciones | 7,21 M |
Máximo/mínimo de 52 semanas | 22,44 € - 0,67 € |
| Dividendos | No |
Beta | -0,05 |
Ratio P/E | -17,67 |
Ratio PEG | 0,59 |
Ratio P/B | 3,08 |
Ratio P/S | 0,00 |
Perfil de la empresa
Evolva Holding SA descubre, investiga, desarrolla y comercializa ingredientes de origen natural para su uso en sabores y fragancias, ingredientes para la salud, protección de la salud y otros sectores en Suiza, Estados Unidos y a nivel internacional. Ofrece diversos ingredientes que incluyen Veri-te Resveratrol, un polifenol de origen natural que se encuentra de forma natural en las uvas y otras plantas, como los cacahuetes, los arándanos rojos y las bayas; L-Arabinosa, un agente aromatizante utilizado en la reacción de Maillard; Valenceno, un componente aromático de los cítricos y de sustancias odoríferas derivadas de cítricos; Nootkatona, un ingrediente aromático del pomelo obtenido mediante la oxidación bioquímica del valenceno; y Vainillina, un componente principal del extracto de vainilla. La empresa fue fundada en 2004 y tiene su sede en Reinach, Suiza.
| Nombre | EVOLVA N |
| CEO | Gerhard Lobmaier |
| Sede | Reinach,
bl Suiza |
| Sitio web | |
| Salida a bolsa | 03/05/2005 |
| Empleados | 49 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
SIX | EVE.SW |
Frankfurt | ADF.F |
London | 0QQJ.L |
München | ADF.MU |